Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cordyceps cicadae mycelium
- Development stage
- Phase 3
- Lead developer
- Shanghai Institute of Pharmaceutical Industry
- Administration
- Oral
01
Overview
Cordyceps cicadae mycelium is a pharmaceutical-grade fungal product developed by the Shanghai Institute of Pharmaceutical Industry (SIPI) for the treatment of chronic kidney disease (CKD). Derived from the mycelium of the fungus *Isaria cicadae* (also known as *Cordyceps cicadae*), it is produced through large-scale submerged fermentation. The drug exerts its therapeutic effects primarily by inhibiting the TGF-beta1/Smad signaling pathway, which reduces renal fibrosis and slows disease progression. It also demonstrates anti-inflammatory and antioxidant properties, helping to lower serum creatinine levels and reduce proteinuria. It has been evaluated in late-stage clinical trials in China as a modernized traditional medicine for renal protection.
- Other names
- Isaria cicadae myceliumPaecilomyces cicadae myceliumJin Chan HuaChan Hua
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA3 (Adenosine A3 receptor)JNK (Mitogen-activated protein kinase kinase kinase family)PGHS-1 (Prostaglandin G/H Synthase 1)TP53 (Cellular Tumor Antigen p53 R175H)SMAD3 (SMAD family member 3)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on cordyceps cicadae mycelium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cordyceps cicadae mycelium.